Cancer News

New Standard of Care for Treatment of Resectable Gastric Cancer (10/03/2017)

The superiority of docetaxel based triplet therapy over standard care in patients with resectable esophago-gastric cancer has been confirmed in late-breaking results from the FLOT4 trial presented at the ESMO 2017 Congress in Madrid.1 Survival in resectable esophago-gastric cancer is poor. Five-year overall survival is around 25% with surgery, and is increased to 36% by …

Continue reading "New Standard of Care for Treatment of Resectable Gastric Cancer"

The US Food and Drug Administration has Expanded the Approval of the Precision Cancer Medicine Keytruda for Treatment of Gastric Cancer (09/25/2017)

Keytruda (Pembrolizumab) is now indicated for patients with recurrent locally advanced or metastatic gastric or gastro-esophogeal junction adenocarcinoma. Patients eligible for keytruda therapy under this new indication must have PD-L1-expressing tumors, and must demonstrate disease progression after two or more prior lines of therapy – including fluoropyrimidine- and platinum-containing chemotherapy and, in some cases, HER2/neu-targeted …

Continue reading "The US Food and Drug Administration has Expanded the Approval of the Precision Cancer Medicine Keytruda for Treatment of Gastric Cancer"

Proton Beam Therapy May Improve Outcomes for Esophageal Cancer (01/23/2017)

Currently a standard treatment for several gastrointestinal cancers (GI) combines the use of chemotherapy and radiation followed by surgical resection. Radiation may be part of the treatment strategy for select cancers of the esophagus, anus, rectum, pancreatic, or small intestine. This treatment approach is often associated with improved outcomes but the radiation may also cause …

Continue reading "Proton Beam Therapy May Improve Outcomes for Esophageal Cancer"

Should HER2 Testing Be Routinely Performed in Patients with Gastric Cancer? (12/08/2016)

The short answer is yes! New evidence-based guidelines for human epidermal growth factor receptor 2 (HER2) testing in advanced gastric and gastroesophageal adenocarcinoma (GEA) have been released jointly by the College of American Pathologists (CAP), American Society for Clinical Pathology (ASCP), and American Society of Clinical Oncology (ASCO). Currently, HER2 is the only marker that can be … Continue reading "Should HER2 Testing Be Routinely Performed in Patients with Gastric Cancer?"

It’s GERD Awareness Week–November 20th (11/20/2016)

It’s that time of year again when there is a tendency to overindulge in a mélange of delicious foods. Although many people may only suffer discomfort from over eating, another group of people suffer from the far more troublesome and chronic disorder of GERD—and it isn’t just over the holidays, nor is it simply from … Continue reading "It’s GERD Awareness Week–November 20th"

Another Study Confirms That Daily Aspirin Lowers Risk of Colorectal & Other GI Tract Cancers (05/09/2016)

The regular use of aspirin significantly reduces the overall risk of cancer, especially colorectal and other gastrointestinal tract cancers, according to a study published in JAMA Oncology.1 The recent report supports the results of previous clinical studies that have also demonstrated that the daily use of aspirin reduces the risk of death from several common cancers, including lung, … Continue reading "Another Study Confirms That Daily Aspirin Lowers Risk of Colorectal & Other GI Tract Cancers"